- Home
- LRE vs SLGL Comparison
LRE vs SLGL Comparison
Compare LRE & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- SLGL
- Stock Information
- Founded
- LRE 2001
- SLGL 1997
- Country
- LRE Japan
- SLGL Israel
- Employees
- LRE N/A
- SLGL N/A
- Industry
- LRE
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- SLGL Health Care
- Exchange
- LRE Nasdaq
- SLGL Nasdaq
- Market Cap
- LRE 17.6M
- SLGL 19.3M
- IPO Year
- LRE 2023
- SLGL 2018
- Fundamental
- Price
- LRE $1.74
- SLGL $7.26
- Analyst Decision
- LRE
- SLGL Buy
- Analyst Count
- LRE 0
- SLGL 1
- Target Price
- LRE N/A
- SLGL $40.00
- AVG Volume (30 Days)
- LRE 25.4K
- SLGL 25.3K
- Earning Date
- LRE 07-30-2015
- SLGL 08-15-2025
- Dividend Yield
- LRE N/A
- SLGL N/A
- EPS Growth
- LRE N/A
- SLGL N/A
- EPS
- LRE 0.29
- SLGL N/A
- Revenue
- LRE $117,804,154.00
- SLGL $12,103,000.00
- Revenue This Year
- LRE N/A
- SLGL N/A
- Revenue Next Year
- LRE N/A
- SLGL $31.17
- P/E Ratio
- LRE $6.38
- SLGL N/A
- Revenue Growth
- LRE 8.82
- SLGL 603.66
- 52 Week Low
- LRE $1.10
- SLGL $3.34
- 52 Week High
- LRE $2.60
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- LRE 63.60
- SLGL 52.97
- Support Level
- LRE $1.64
- SLGL $7.02
- Resistance Level
- LRE $1.83
- SLGL $7.58
- Average True Range (ATR)
- LRE 0.16
- SLGL 0.37
- MACD
- LRE -0.02
- SLGL 0.02
- Stochastic Oscillator
- LRE 40.86
- SLGL 41.28
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.